Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer
Identifieur interne : 004C48 ( Main/Exploration ); précédent : 004C47; suivant : 004C49Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer
Auteurs : John A. Vargo [États-Unis] ; Gregory J. Kubicek [États-Unis] ; Robert L. Ferris [États-Unis] ; Umamaheswar Duvvuri [États-Unis] ; Jonas T. Johnson [États-Unis] ; James Ohr [États-Unis] ; David A. Clump [États-Unis] ; Steven Burton [États-Unis] ; Dwight E. Heron [États-Unis]Source :
- The Laryngoscope [ 0023-852X ] ; 2014-07.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Association thérapeutique, Carcinome épidermoïde (), Carcinome épidermoïde (diagnostic), Carcinome épidermoïde (mortalité), Cétuximab, Dosimétrie en radiothérapie, Femelle, Humains, Incidence, Mâle, Qualité de vie, Radiochirurgie (), Radiothérapie adjuvante (), Récepteur du facteur de croissance épidermique, Récidive tumorale locale (), Récidive tumorale locale (épidémiologie), Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie (tendances), Thérapie de rattrapage (), Tumeurs de la tête et du cou (), Tumeurs de la tête et du cou (diagnostic), Tumeurs de la tête et du cou (mortalité), États-Unis d'Amérique (épidémiologie), Études de suivi, Études rétrospectives.
- MESH :
- diagnostic : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- mortalité : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- tendances : Taux de survie.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antinéoplasiques.
- épidémiologie : Récidive tumorale locale, États-Unis d'Amérique.
- Adulte, Adulte d'âge moyen, Association thérapeutique, Carcinome épidermoïde, Cétuximab, Dosimétrie en radiothérapie, Femelle, Humains, Incidence, Mâle, Qualité de vie, Radiochirurgie, Radiothérapie adjuvante, Récepteur du facteur de croissance épidermique, Récidive tumorale locale, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Thérapie de rattrapage, Tumeurs de la tête et du cou, Études de suivi, Études rétrospectives.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Agents (therapeutic use), Carcinoma, Squamous Cell (diagnosis), Carcinoma, Squamous Cell (mortality), Carcinoma, Squamous Cell (therapy), Cetuximab, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Head and Neck Neoplasms (diagnosis), Head and Neck Neoplasms (mortality), Head and Neck Neoplasms (therapy), Humans, Incidence, Male, Middle Aged, Neoplasm Recurrence, Local (epidemiology), Neoplasm Recurrence, Local (therapy), Neoplasm Staging, Quality of Life, Radiosurgery (methods), Radiotherapy Dosage, Radiotherapy, Adjuvant (methods), Receptor, Epidermal Growth Factor, Retrospective Studies, Salvage Therapy (methods), Survival Rate (trends), United States (epidemiology).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- geographic , epidemiology : United States.
- diagnosis : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- epidemiology : Neoplasm Recurrence, Local.
- methods : Radiosurgery, Radiotherapy, Adjuvant, Salvage Therapy.
- mortality : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Recurrence, Local.
- trends : Survival Rate.
- Adult, Aged, Aged, 80 and over, Cetuximab, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Neoplasm Staging, Quality of Life, Radiotherapy Dosage, Receptor, Epidermal Growth Factor, Retrospective Studies.
Abstract
Locoregional recurrence remains the primary failure pattern following salvage surgery for previously irradiated head and neck cancer; randomized trials have suggested a complimentary role for adjuvant chemotherapy and conventional reirradiation at the expense of significant increases in toxicity. We aimed to identify if stereotactic body radiotherapy (SBRT) ± cetuximab improves tumor control while reducing treatment‐related toxicity following salvage surgery.
Url:
DOI: 10.1002/lary.24441
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C69
- to stream Istex, to step Curation: 000C69
- to stream Istex, to step Checkpoint: 000767
- to stream PubMed, to step Corpus: 002594
- to stream PubMed, to step Curation: 002584
- to stream PubMed, to step Checkpoint: 002584
- to stream Ncbi, to step Merge: 000393
- to stream Ncbi, to step Curation: 000393
- to stream Ncbi, to step Checkpoint: 000393
- to stream Main, to step Merge: 004E85
- to stream Main, to step Curation: 004C48
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer</title>
<author><name sortKey="Vargo, John A" sort="Vargo, John A" uniqKey="Vargo J" first="John A." last="Vargo">John A. Vargo</name>
</author>
<author><name sortKey="Kubicek, Gregory J" sort="Kubicek, Gregory J" uniqKey="Kubicek G" first="Gregory J." last="Kubicek">Gregory J. Kubicek</name>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
</author>
<author><name sortKey="Duvvuri, Umamaheswar" sort="Duvvuri, Umamaheswar" uniqKey="Duvvuri U" first="Umamaheswar" last="Duvvuri">Umamaheswar Duvvuri</name>
</author>
<author><name sortKey="Johnson, Jonas T" sort="Johnson, Jonas T" uniqKey="Johnson J" first="Jonas T." last="Johnson">Jonas T. Johnson</name>
</author>
<author><name sortKey="Ohr, James" sort="Ohr, James" uniqKey="Ohr J" first="James" last="Ohr">James Ohr</name>
</author>
<author><name sortKey="Clump, David A" sort="Clump, David A" uniqKey="Clump D" first="David A." last="Clump">David A. Clump</name>
</author>
<author><name sortKey="Burton, Steven" sort="Burton, Steven" uniqKey="Burton S" first="Steven" last="Burton">Steven Burton</name>
</author>
<author><name sortKey="Heron, Dwight E" sort="Heron, Dwight E" uniqKey="Heron D" first="Dwight E." last="Heron">Dwight E. Heron</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:356630373665BE1F62996773A72C779790BC1714</idno>
<date when="2014" year="2014">2014</date>
<idno type="doi">10.1002/lary.24441</idno>
<idno type="url">https://api.istex.fr/document/356630373665BE1F62996773A72C779790BC1714/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C69</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C69</idno>
<idno type="wicri:Area/Istex/Curation">000C69</idno>
<idno type="wicri:Area/Istex/Checkpoint">000767</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000767</idno>
<idno type="wicri:doubleKey">0023-852X:2014:Vargo J:adjuvant:stereotactic:body</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:24123056</idno>
<idno type="wicri:Area/PubMed/Corpus">002594</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002594</idno>
<idno type="wicri:Area/PubMed/Curation">002584</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002584</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002584</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002584</idno>
<idno type="wicri:Area/Ncbi/Merge">000393</idno>
<idno type="wicri:Area/Ncbi/Curation">000393</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000393</idno>
<idno type="wicri:Area/Main/Merge">004E85</idno>
<idno type="wicri:Area/Main/Curation">004C48</idno>
<idno type="wicri:Area/Main/Exploration">004C48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer</title>
<author><name sortKey="Vargo, John A" sort="Vargo, John A" uniqKey="Vargo J" first="John A." last="Vargo">John A. Vargo</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubicek, Gregory J" sort="Kubicek, Gregory J" uniqKey="Kubicek G" first="Gregory J." last="Kubicek">Gregory J. Kubicek</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Division of Head and Neck Surgery, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duvvuri, Umamaheswar" sort="Duvvuri, Umamaheswar" uniqKey="Duvvuri U" first="Umamaheswar" last="Duvvuri">Umamaheswar Duvvuri</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Division of Head and Neck Surgery, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Jonas T" sort="Johnson, Jonas T" uniqKey="Johnson J" first="Jonas T." last="Johnson">Jonas T. Johnson</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Division of Head and Neck Surgery, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ohr, James" sort="Ohr, James" uniqKey="Ohr J" first="James" last="Ohr">James Ohr</name>
<affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, and Division of Medical Oncology , Department of Medicine, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clump, David A" sort="Clump, David A" uniqKey="Clump D" first="David A." last="Clump">David A. Clump</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burton, Steven" sort="Burton, Steven" uniqKey="Burton S" first="Steven" last="Burton">Steven Burton</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heron, Dwight E" sort="Heron, Dwight E" uniqKey="Heron D" first="Dwight E." last="Heron">Dwight E. Heron</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Division of Head and Neck Surgery, University of Pittsburgh Cancer Institute, Pennsylvania, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">The Laryngoscope</title>
<title level="j" type="alt">THE LARYNGOSCOPE</title>
<idno type="ISSN">0023-852X</idno>
<idno type="eISSN">1531-4995</idno>
<imprint><biblScope unit="vol">124</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1579">1579</biblScope>
<biblScope unit="page" to="1584">1584</biblScope>
<biblScope unit="page-count">6</biblScope>
<date type="published" when="2014-07">2014-07</date>
</imprint>
<idno type="ISSN">0023-852X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0023-852X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Carcinoma, Squamous Cell (diagnosis)</term>
<term>Carcinoma, Squamous Cell (mortality)</term>
<term>Carcinoma, Squamous Cell (therapy)</term>
<term>Cetuximab</term>
<term>Combined Modality Therapy</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Head and Neck Neoplasms (diagnosis)</term>
<term>Head and Neck Neoplasms (mortality)</term>
<term>Head and Neck Neoplasms (therapy)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Recurrence, Local (epidemiology)</term>
<term>Neoplasm Recurrence, Local (therapy)</term>
<term>Neoplasm Staging</term>
<term>Quality of Life</term>
<term>Radiosurgery (methods)</term>
<term>Radiotherapy Dosage</term>
<term>Radiotherapy, Adjuvant (methods)</term>
<term>Receptor, Epidermal Growth Factor</term>
<term>Retrospective Studies</term>
<term>Salvage Therapy (methods)</term>
<term>Survival Rate (trends)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Association thérapeutique</term>
<term>Carcinome épidermoïde ()</term>
<term>Carcinome épidermoïde (diagnostic)</term>
<term>Carcinome épidermoïde (mortalité)</term>
<term>Cétuximab</term>
<term>Dosimétrie en radiothérapie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Mâle</term>
<term>Qualité de vie</term>
<term>Radiochirurgie ()</term>
<term>Radiothérapie adjuvante ()</term>
<term>Récepteur du facteur de croissance épidermique</term>
<term>Récidive tumorale locale ()</term>
<term>Récidive tumorale locale (épidémiologie)</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Taux de survie (tendances)</term>
<term>Thérapie de rattrapage ()</term>
<term>Tumeurs de la tête et du cou ()</term>
<term>Tumeurs de la tête et du cou (diagnostic)</term>
<term>Tumeurs de la tête et du cou (mortalité)</term>
<term>États-Unis d'Amérique (épidémiologie)</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiosurgery</term>
<term>Radiotherapy, Adjuvant</term>
<term>Salvage Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Taux de survie</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Récidive tumorale locale</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cetuximab</term>
<term>Combined Modality Therapy</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Quality of Life</term>
<term>Radiotherapy Dosage</term>
<term>Receptor, Epidermal Growth Factor</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association thérapeutique</term>
<term>Carcinome épidermoïde</term>
<term>Cétuximab</term>
<term>Dosimétrie en radiothérapie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Mâle</term>
<term>Qualité de vie</term>
<term>Radiochirurgie</term>
<term>Radiothérapie adjuvante</term>
<term>Récepteur du facteur de croissance épidermique</term>
<term>Récidive tumorale locale</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Thérapie de rattrapage</term>
<term>Tumeurs de la tête et du cou</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Locoregional recurrence remains the primary failure pattern following salvage surgery for previously irradiated head and neck cancer; randomized trials have suggested a complimentary role for adjuvant chemotherapy and conventional reirradiation at the expense of significant increases in toxicity. We aimed to identify if stereotactic body radiotherapy (SBRT) ± cetuximab improves tumor control while reducing treatment‐related toxicity following salvage surgery.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
<settlement><li>Pittsburgh</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Vargo, John A" sort="Vargo, John A" uniqKey="Vargo J" first="John A." last="Vargo">John A. Vargo</name>
</region>
<name sortKey="Burton, Steven" sort="Burton, Steven" uniqKey="Burton S" first="Steven" last="Burton">Steven Burton</name>
<name sortKey="Clump, David A" sort="Clump, David A" uniqKey="Clump D" first="David A." last="Clump">David A. Clump</name>
<name sortKey="Duvvuri, Umamaheswar" sort="Duvvuri, Umamaheswar" uniqKey="Duvvuri U" first="Umamaheswar" last="Duvvuri">Umamaheswar Duvvuri</name>
<name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<name sortKey="Heron, Dwight E" sort="Heron, Dwight E" uniqKey="Heron D" first="Dwight E." last="Heron">Dwight E. Heron</name>
<name sortKey="Heron, Dwight E" sort="Heron, Dwight E" uniqKey="Heron D" first="Dwight E." last="Heron">Dwight E. Heron</name>
<name sortKey="Heron, Dwight E" sort="Heron, Dwight E" uniqKey="Heron D" first="Dwight E." last="Heron">Dwight E. Heron</name>
<name sortKey="Johnson, Jonas T" sort="Johnson, Jonas T" uniqKey="Johnson J" first="Jonas T." last="Johnson">Jonas T. Johnson</name>
<name sortKey="Kubicek, Gregory J" sort="Kubicek, Gregory J" uniqKey="Kubicek G" first="Gregory J." last="Kubicek">Gregory J. Kubicek</name>
<name sortKey="Ohr, James" sort="Ohr, James" uniqKey="Ohr J" first="James" last="Ohr">James Ohr</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Amérique |area= PittsburghV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:356630373665BE1F62996773A72C779790BC1714 |texte= Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer }}
This area was generated with Dilib version V0.6.38. |